Olpinat (Olanzapine)

Olanzapine, the active ingredient in Olpinat, is an atypical antipsychotic presented as a 10 mg tablet for oral use. It treats schizophrenia and bipolar I disorder in adults and adolescents. GNH USA supplies Olpinat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olpinat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olpinat is an atypical antipsychotic that acts on dopamine and serotonin pathways to manage serious mental health conditions.

- Schizophrenia: reduces positive and negative symptoms and helps maintain long‑term stability. - Bipolar I disorder (manic episodes): controls acute mania and supports maintenance therapy. - Schizoaffective disorder: alleviates psychotic features and mood symptoms. - Psychotic depression: augments antidepressant treatment to improve depressive and psychotic symptoms. - Agitation associated with schizophrenia or bipolar disorder: provides rapid calming effect.

Olpinat may cause a range of adverse reactions, most of which are dose‑dependent and reversible upon discontinuation.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or feeling of being slowed down. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Elevated triglycerides: changes in lipid metabolism. - Orthostatic hypotension: drop in blood pressure on standing.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Hyperglycaemia or new‑onset diabetes mellitus. - Tardive dyskinesia: involuntary, repetitive movements. - Seizures: especially in patients with pre‑existing seizure disorders. - Severe leukopenia or agranulocytosis. - Hepatotoxicity: abnormal liver function tests.

When prescribing Olpinat, clinicians should evaluate patient history and monitor for specific risks.

- Metabolic monitoring: regularly check weight, fasting glucose, and lipid profile. - Cardiovascular assessment: monitor blood pressure and heart rate, especially during initiation. - CNS effects: advise patients about sedation and avoid operating heavy machinery until they know how the drug affects them. - Pregnancy and lactation: use only if benefits outweigh risks; discuss potential fetal exposure. - Elderly patients: start at lower doses and monitor for orthostatic hypotension and falls. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olpinat can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase olanzapine plasma levels. - CNS depressants (benzodiazepines, opioids): additive sedation and respiratory depression. - Anticholinergic agents: heightened risk of anticholinergic toxicity.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., tamoxifen): may reduce conversion to active metabolites. - Smoking: induces CYP1A2, potentially lowering olanzapine concentrations. - Lithium: combined use may increase risk of neurotoxicity.